← Markets

Cullinan Therapeutics, Inc.

CGEM · NASDAQ

Market closed$17.69$1.28 (+7.80%)After hours $17.69 · 0.00%

Key statistics

Previous close$16.41
Open$16.13
Day high$17.89
Day low$16.00
52-week high$19.43
52-week low$5.68
Market cap1.09B
Volume579.54K
Average volume1.07M
P/E ratio-5.26
Forward P/E—
EPS-3.36
Dividend yield0.00%

Market context

Why it moved

CGEM surged higher as technical analysts highlighted a highly favorable risk-reward trading setup with a mid-channel oscillation pattern targeting significant upside gains, drawing increased investor attention and buying momentum.

FacebookMarketbeatInstagramInstagramInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Cullinan Therapeutics surged nearly 8% amid a broadly favorable backdrop for biopharma stocks, with UBS upgrading its outlook on the healthcare sector and noting that biotechnology stands to benefit from a warming M&A environment and product catalysts. The move came as sector peers like UnitedHealth and Abbott posted strong Q2 earnings beats, lifting sentiment across healthcare broadly, even as the wider market faced headwinds from chip stock weakness and U.S.-Iran tensions.

7.8001

July 17, 2026Cullinan Therapeutics tumbled sharply, closing down nearly 8% against a backdrop of broad healthcare sector weakness. The XLV healthcare ETF also faced selling pressure on the day as investors digested mixed signals across the sector, including Elevance Health's underwhelming guidance raise and ongoing concerns about medical cost trends. No company-specific catalyst was identified in available sources, suggesting the steep decline may reflect broader sector rotation out of small-cap biopharma names amid a risk-off tone in healthcare, compounded by a wider market pullback led by tech and chip stocks on Thursday.

-7.9641

July 15, 2026Cullinan Therapeutics closed essentially flat amid a mixed backdrop for the broader healthcare sector, where State Street upgraded its sector outlook to positive for Q3 2026 citing 19.3% expected earnings growth in 2027 driven by biopharma innovations. While the XLV healthcare ETF held steady, headwinds from HCA Healthcare's profit forecast cut and concerns over rising uninsured patients weighed on sentiment in parts of the sector. Biotech names like Cullinan face a nuanced environment: institutional investors remain underweight healthcare at 15-year valuation lows, and UBS has designated the sector a key allocation target on improving fundamentals and M&A tailwinds.

0.3376

July 9, 2026Cullinan Therapeutics closed essentially flat amid a broader macro backdrop dominated by renewed US-Iran geopolitical tensions and a healthcare sector that has been outperforming the broader market. The stock's below-average volume reflects limited company-specific catalysts, with the most recent notable development being the CSO's routine sale of 8,000 shares on July 6 under a pre-arranged 10b5-1 plan — viewed as a neutral insider transaction. Healthcare broadly has posted back-to-back weeks of sector-leading gains, with XLV up over 13% in the prior two weeks, offering a supportive backdrop for clinical-stage pharma names even as macro volatility from oil price spikes and AI sector weakness weighs on broader equities.

-0.2713

July 2, 2026Cullinan Therapeutics rose over 2% as Clear Street named it a top biotech pick for H2 2026, assigning a Buy rating with a $46 price target — well above current levels. The firm highlighted CLN-978's CD19 x CD3 bispecific profile as 'game-changing' among key opinion leaders, with its BCMA-directed partner velinotamig positioning the company across multi-billion-dollar autoimmune markets. Upcoming data readouts — rheumatoid arthritis in Q3 and SLE/Sjogren's in Q4 — are seen as key catalysts, while an FDA Orphan Drug Designation for CLN-049 in AML adds further pipeline momentum. The healthcare sector ETF (XLV) also traded near 52-week highs, providing a supportive backdrop.

2.0255

July 2, 2026Cullinan Therapeutics fell sharply, underperforming the broader healthcare sector (XLV essentially flat) as chip-led tech weakness dragged on broader market sentiment to start the new quarter. Despite the decline, Clear Street named CGEM one of its top biotech stocks to watch in H2 2026, assigning a Buy rating with a $46 price target — more than double the current share price — citing CLN-978's CD19 x CD3 profile as 'game-changing' among key opinion leaders and highlighting near-term catalysts including rheumatoid arthritis data expected in Q3 and SLE/Sjogren's data in Q4.

-5.1071

July 1, 2026Cullinan Therapeutics shares closed modestly lower, underperforming the broader healthcare sector, which has been one of the strongest-performing areas of the market amid sector rotation away from large-cap tech. The company's lead asset, zipalertinib, remains a key focus as it is highlighted in a new DelveInsight EGFR-NSCLC market forecast report projecting the EGFR inhibitor market to grow from $7B to $16B by 2036, with Cullinan Oncology/Taiho Pharmaceutical listed among key players. Broader pharma names face heightened regulatory scrutiny, while below-average volume signals limited conviction from investors heading into the half-year close.

-1.1401

June 27, 2026Cullinan Therapeutics closed modestly lower, retreating slightly after a remarkable ~127% one-year run fueled by strong Phase 1 data for its T cell engager candidates CLN-978 and velinotamig in autoimmune diseases like SLE and rheumatoid arthritis. The stock, which surged over 30% earlier this month on "immune reset" therapy data and hit a 52-week high near $17.97, saw above-average trading volume as investors digested the rally's sustainability — with analysts at William Blair (Outperform) and Stifel (Buy, $28 PT) remaining bullish even as the broader healthcare sector posted its strongest weekly gain since June 2022.

-0.4329

TradingView · July 16, 2026Cullinan Therapeutics shares Phase 1 CLN-978 data showing deep B-cell depletion and clinical responsesSimply Wall Street · June 24, 2026Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data – Has The Bull Case Changed?Seeking Alpha · June 11, 2026Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM)GlobeNewswire · June 10, 2026Cullinan Therapeutics Shares New Clinical Data Across ItsQuiver Quantitative · June 6, 2026Cullinan Therapeutics Reports Positive Clinical Data for CLN-978 in Treating Systemic Lupus Erythematosus and Rheumatoid Arthritis | CGEM Stock NewsFierce Biotech · June 6, 2026‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEsSeeking Alpha · April 30, 2026Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst (NASDAQ:CGEM)PR Newswire · November 20, 2025Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGF
Benzinga · June 11, 2026Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $37 Price Target
Mt Newswire · June 10, 2026Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps
Benzinga · June 10, 2026Cullinan Therapeutics Reports Clinical Data And Outlines Global Clinical Development Plans For CLN-978, CD19xCD3 T Cell Engager, And Velinotamig, BCMAxCD3 T Cell Engager
Benzinga · June 8, 2026Reported Saturday, Cullinan's CLN-978 Delivers Deep B Cell Depletion And Clinical Remissions In SLE And RA Patients Following Single Target Dose In Phase 1 Trial
Benzinga · May 26, 2026Cullinan Therapeutics To Host An Immunology Day Event in New York City For Analysts And Institutional Investors On June 10
Mt Newswire · May 19, 2026Cullinan Therapeutics Gets FDA Orphan Drug Designation for CLN-049 in Acute Myeloid Leukemia
Benzinga · May 19, 2026The FDA Grants Orphan Drug Designation To Cullinan Therapeutics' CLN-049 For Relapsed/Refractory Acute Myeloid Leukemia
Benzinga · May 18, 2026Cullinan Therapeutics To Reveal Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Peers

S&P 500SPX · $7,457.69-1.01%ACADIA Pharmaceuticals Inc.ACAD · $25.60-0.12%Tango Therapeutics, Inc.TNGX · $28.56+3.33%Denali Therapeutics Inc.DNLI · $23.29+2.46%NewAmsterdam Pharma Company N.V.NAMS · $31.68+2.03%Structure Therapeutics Inc.GPCR · $48.48+5.32%Vertex Pharmaceuticals IncorporatedVRTX · $485.65-0.08%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%argenx SEARGX · $860.55+0.30%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%BridgeBio Pharma, Inc.BBIO · $81.38+1.34%Ionis Pharmaceuticals, Inc.IONS · $54.39-0.48%